# Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS

> **NCT02921061** · PHASE1,PHASE2 · COMPLETED · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 28 (actual)

## Conditions studied

- Mixed Phenotype Acute Leukemia
- Previously Treated Myelodysplastic Syndrome
- Recurrent Adult Acute Myeloid Leukemia
- Recurrent High Risk Myelodysplastic Syndrome
- Refractory Acute Myeloid Leukemia
- Refractory High Risk Myelodysplastic Syndrome
- Untreated Adult Acute Myeloid Leukemia

## Interventions

- **DRUG:** Cladribine
- **DRUG:** Cytarabine
- **DRUG:** Decitabine
- **BIOLOGICAL:** Filgrastim
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Mitoxantrone Hydrochloride

## Key facts

- **NCT ID:** NCT02921061
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-17
- **Primary completion:** 2018-10-24
- **Final completion:** 2018-10-24
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2020-03-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02921061

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02921061, "Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02921061. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*